EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cytochrome P450 2D6 Poor Metabolizers and Risperidone Treatment Failure: A 1‐Year Longitudinal Study

Marianna Piras iD, Setareh Ranjbar, Séverine Crettol iD, Frederik Vandenberghe iD, Nicolas Ansermot iD, Carole Grandjean, Giorgio Pistis, Martin Preisig, Logos Curtis, Franziska Gamma, Didier Delessert, Julien Elowe und 4 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3691 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Marianna Piras und 15 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Risperidone, Antipsychotic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cytochrome P450 2D6 (CYP2D6) metabolizes around 20% of currently prescribed medications, including the antipsychotic risperidone. Previous studies reported greater odds of switching antipsychotic medication from risperidone among CYP2D6 poor metabolizers (PM) without considering treatment duration up to the switch. Risperidone treatment failure, defined as risperidone treatment duration up to switching medication, was analyzed among 515 patients of the PsyMetab cohort using Kaplan–Meier estimates with log‐rank tests and Cox multivariate regression. Risperidone‐to‐paliperidone ratios were higher among CYP2D6 PMs (median: 2.78) vs. the other phenotypes (median: 0.14, P < 0.001). After 1 year of treatment, the proportion of patients who switched from risperidone was 44%. This proportion was increased to 70% among PMs, vs. 42% among the other CYP2D6 phenotypes ( P = 0.026). PMs' risk of switching increased over time (interaction PM*treatment duration: 1.01; P = 0.011), becoming statistically significant after 3 months of treatment, with 1.79 ( P = 0.028), 3.7 times ( P < 0.001) and 16.3 times higher ( P = 0.001) risk of switch at 3, 6, and 12 months, respectively (95% confidence intervals: 1.07–3.01, 1.91–7.17, and 3.13–85.37, respectively). Considering a pharmacogenetic‐guided treatment, the number of patients needed to genotype to find one PM and lower the switching proportion from 70% to 42% would be 65. In conclusion, CYP2D6 PM status presented an increased risk of switching from risperidone over 1 year of treatment, the risk increasing over time and becoming statistically significant after the first 3 months of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2D6RisperidoneAntipsychotic AgentsHumansMaleFemaleMiddle AgedLongitudinal StudiesAdultTreatment FailurePhenotypeDrug SubstitutionAgedTime FactorsPaliperidone Palmitate

Substanzen

Cytochrome P-450 CYP2D6RisperidoneAntipsychotic AgentsPaliperidone Palmitate

Autor:innen und Institutionen

  • Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
  • Department of Psychiatry, Center for Psychiatric Epidemiology and Psychopathology, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
  • Department of Psychiatry, Geneva University Hospitals, Geneva, Switzerland.
  • Les Toises Psychiatry and Psychotherapy Center, Lausanne, Switzerland.
  • Prison Medicine and Psychiatry Service, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
  • Service of Adult Psychiatry North-West, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.

ORCID-Profile: Marianna Piras, Séverine Crettol, Frederik Vandenberghe, Nicolas Ansermot

Zitieren

APA

Piras, M., Ranjbar, S., Crettol, S., Vandenberghe, F., Ansermot, N., Grandjean, C., Pistis, G., Preisig, M., Curtis, L., Gamma, F., Delessert, D., Elowe, J., Plessen, K. J., von Gunten, A., Conus, P., & Eap, C. B. (2025). Cytochrome P450 2D6 Poor Metabolizers and Risperidone Treatment Failure: A 1‐Year Longitudinal Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3691

Vancouver

Piras M, Ranjbar S, Crettol S, Vandenberghe F, Ansermot N, Grandjean C, et al. Cytochrome P450 2D6 Poor Metabolizers and Risperidone Treatment Failure: A 1‐Year Longitudinal Study. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3691

BibTeX
@article{Piras2025,
  author = {Piras, Marianna and Ranjbar, Setareh and Crettol, Séverine and Vandenberghe, Frederik and Ansermot, Nicolas and Grandjean, Carole and Pistis, Giorgio and Preisig, Martin and Curtis, Logos and Gamma, Franziska and Delessert, Didier and Elowe, Julien and Plessen, Kerstin Jessica and von Gunten, Armin and Conus, Philippe and Eap, Chin Bin},
  title = {Cytochrome P450 2D6 Poor Metabolizers and Risperidone Treatment Failure: A 1‐Year Longitudinal Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3691}
}
Kostenlos starten →